Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private PlacementBusiness Wire • 03/07/24
MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety DisorderBusiness Wire • 03/07/24
MindMed to Host Conference Call and Webcast to Discuss 2023 Financial Results and Provide Business UpdateBusiness Wire • 02/22/24
MindMed to Participate in the 34th Annual Oppenheimer Healthcare Life Sciences ConferenceBusiness Wire • 02/07/24
Why one backer of MDMA therapy sees ‘exponential' growth following FDA approval this yearMarket Watch • 01/03/24
Mind Medicine's MM-120 shows promise in Phase 2b trial for Generalized Anxiety DisorderProactive Investors • 12/14/23
MindMed announces positive results in trial of LSD as a treatment for generalized anxiety disorderMarket Watch • 12/14/23
MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety DisorderBusiness Wire • 12/14/23
MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Business UpdateBusiness Wire • 10/26/23
MindMed Completes Enrollment of Phase 2a Trial of MM-120 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)Business Wire • 10/24/23
MindMed to Present Data on the Preclinical Activity of MM-402 at the 36th Annual European College of Neuropsychopharmacology (ECNP) CongressBusiness Wire • 10/03/23
MindMed to Participate in the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry SummitBusiness Wire • 09/14/23